Glenmark Life Sciences was incorporated on June 23, 2011 as ‘Zorg Laboratories Private Limited’. The company developes and manufactures select high value, non-commoditized active pharmaceutical ingredients in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes
| Bidding Dates |
|---|
| 27 Jul 2021 - 29 Jul 2021 |
| Subscription |
|---|
| 44.17x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,400 | 1 | 13 | 20 | 21.0 M | ₹695 - ₹720 | 82.84 % | ₹14610.4 M - ₹15136.0 M | RHP DOC |
Alivus Life Sciences IPO SUBSCRIPTION STATUS
29 Jul '21Alivus Life Sciences IPO overall subscription rate was 44.17 times the total available shares
Alivus Life Sciences IPO retail subscription rate was 14.63 times in the retail segment
Alivus Life Sciences IPO non-institutional investor subscription rate was 122.54 times in the non-institutional investor category
Alivus Life Sciences IPO Qualified Institutional Bidder subscription rate was 36.97 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
29 Jul 2021 (Day 3) | 14.63x | 122.54x | 36.97x |
28 Jul 2021 (Day 2) | 9.28x | 3.39x | 1.38x |
27 Jul 2021 (Day 1) | 5.17x | 0.86x | 0x |
Alivus Life Sciences FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from operations (Rs in millions) | Cash Flow from operations (Rs in millions) | Free Cash flow (Rs in millions) | Margins |
| FY21 | 3,515.8 | 18,851.7 | 3,881.1 | 3,217.5 | 31.4% |
| FY20 | 3,131.0 | 15,373.1 | 1,950.1 | 1,441.3 | 31.5% |
| FY19 | 1,955.9 | 8,864.2 | 103.5 | 10.3 | 30.6% |
Alivus Life Sciences IPO SUBSCRIPTION STATUS DETAILS
Alivus Life Sciences had 21.0 M shares on offer
Alivus Life Sciences IPO offer price was in the range ₹695 - ₹720
Alivus Life Sciences IPO minimum Investment was ₹14400
Alivus Life Sciences IPO issue size was ₹ 14610.4 M - ₹ 15136.0 M
Alivus Life Sciences had a minimum lot size of 20 Shares per application
Alivus Life Sciences NUMBER OF SHARES ON OFFER
Alivus Life Sciences IPO IMPORTANT DATES
| Issue Open Date | 27 Jul 2021 |
| Issue close Date | 29 Jul 2021 |
| Allotment Date | 03 Aug 2021 |
| Refund Date | 04 Aug 2021 |
| Demat Account Credit Date | 05 Aug 2021 |
| Listing Date | 06 Aug 2021 |
| Listing on Exchange(s) | NSE and BSE |
| Alivus Life Sciences Allotment Status | Exchange |
Alivus Life Sciences IPO subscription opened on 27 Jul 2021, and closed on 29 Jul 2021
IPO allotment for Alivus Life Sciences was finalized on Tuesday, 03 Aug 2021
IPO listing for Alivus Life Sciences was on NSE and BSE on Friday, 06 Aug 2021
Alivus Life Sciences IPO LISTING GAINS
| Issue Price (adjusted) | 720.0 |
| Listing Open Price | 752.0 |
| Listing Close Price | 748.2 |
| Listing Gain% | 4.4% |
| Current Gain% | 84.7% |
Alivus Life Sciences Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | 1329.8 | 16293.7 | 27.1 | 1.3 | 6.3 | 16.9 | 14.2 | 2612.2 | 7.9 | 564.5 | 16.2 | 49.1 | 21.7 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Alivus Life Sciences INFORMATION ON IPO ISSUE
About Alivus Life Sciences
Glenmark Life Sciences was incorporated on June 23, 2011 as ‘Zorg Laboratories Private Limited’. The company developes and manufactures select high value, non-commoditized active pharmaceutical ingredients in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes
Object of the Issue
1. To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
2. To finance capital expenditure requirements.
3. To meet general corporate purposes.
Alivus Life Sciences - PROMOTERS
| Name |
|---|
| Glenmark Pharmaceuticals |
Alivus Life Sciences Book Running Lead Managers
DAM Capital Advisors Limited
glenmark.ipo@damcapital.in
BOB Capital Markets Limited
gls.ipo@bobcaps.in
SBI Capital Markets Limited
gls.ipo@sbicaps.com
Alivus Life Sciences Registrar to the Offer
KFin Technologies Private Limited
glenmark.ipo@kfintech.com
Alivus Life Sciences Strengths
Leading manufacturer
Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management
Export products
Export products in Europe, Latin America, North America, Japan, and the rest of the world
Strong relationships
A strong relationship with leading global generic companies
Financial performance
Proven track record of strong financial performance
Infrastructure
High-quality product manufacturing with R&D infrastructure
Alivus Life Sciences Risks
Dependent on limited customers
The business is dependent on the sale of products to key customers, and the loss of one or more such customers, the deterioration of their financial condition or prospects, or a reduction in their demand for products could adversely affect business, results of operations, financial condition, and cash flows
Dependent on API business
The company derives a significant portion of revenue from its API business
Legal proceedings
The company, promoter and directors are or may be involved in certain legal and regulatory proceedings
IPO FAQs
This IPO consists of an offer for sale of up to Rs 453.6 crore, of 6,300,000 shares. It also consists of a fresh issue of Rs 1,060.0 crore.
The promoter of the company is Glenmark Pharmaceuticals.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 695.0 - 720.0.
The IPO application opens on Jul 27, 2021 and closes on Jul 29, 2021.
The minimum lot size for the IPO is 20. The maximum lot size for the IPO is 260.
For all category investors, the minimum application amount for this IPO is Rs. 14,400.0, the maximum value for this IPO is Rs 187,200.0.
This IPO will be allotted on Aug 03, 2021.
The refund will be credited to your account on Aug 04, 2021.
The allotted shares will be credited to your demat on Aug 05, 2021.
Glenmark Life Sciences Ltd.’s shares listed on the stock exchanges on Aug 06, 2021.